ALBIREO PHARMA, INC. — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/ad1198cb-280f-4bc8-9230-d42b4a5df2a7/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2021 | $-123.5M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-002501 |
| FY 2020 | $-96.3M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-001730 |
| FY 2019 | $-61.1M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-001905 |
| FY 2018 | $-37.9M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-001601 |
| FY 2017 | $-24.6M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-006847 |
| FY 2016 | $-12.3M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-005341 |
| FY 2015 | $-4.7M | 2015-01-01 – 2015-12-31 | evidence 0001564590-17-005341 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).